share_log

Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years

Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years

evolent health(紐交所:EVH)本週回落5.1%,但仍以驚人的33%年均複合增長率回報股東5年
Simply Wall St ·  09/06 22:32

We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing gains over the years. To wit, the Evolent Health, Inc. (NYSE:EVH) share price has soared 313% over five years. And this is just one example of the epic gains achieved by some long term investors. And in the last month, the share price has gained 49%.

我們認爲所有投資者都應該嘗試購買和持有優質的多年贏家。多年來,我們看到了一些真正令人驚訝的收益。以Evolent Health, Inc. (紐交所:EVH)的股價爲例,其股價在過去五年中上漲了313%。這只是一些長期投資者實現的驚人收益的一個例子。最近一個月,股價上漲了49%。

While the stock has fallen 5.1% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

雖然本週股價下跌了5.1%,但值得關注的是長期而言,股票的歷史回報是否受基本面驅動。

Given that Evolent Health didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

鑑於Evolent Health過去十二個月沒有盈利,我們將重點關注營業收入增長,以快速了解其業務發展情況。當一家公司沒有盈利時,我們通常希望看到良好的營業收入增長。有些公司願意推遲盈利以加快收入增長,但在這種情況下,我們希望看到良好的營業收入增長來彌補缺乏盈利的情況。

For the last half decade, Evolent Health can boast revenue growth at a rate of 24% per year. That's well above most pre-profit companies. Arguably, this is well and truly reflected in the strong share price gain of 33%(per year) over the same period. It's never too late to start following a top notch stock like Evolent Health, since some long term winners go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.

在過去的五年裏,Evolent Health每年的營業收入增長率爲24%。這遠遠高於大多數無利潤公司。可以說,這完全反映在同期股價上漲33%(每年)的強勁漲幅中。像Evolent Health這樣的頂級股票始終是一個不錯的投資機會,因爲一些長期贏家會持續贏下去幾十年。從表面上看,這似乎是一個不錯的機會,儘管我們注意到市場情緒已經非常積極。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收益和營收隨時間變化的情況(如果你點擊圖像,可以看到更多細節):

big
NYSE:EVH Earnings and Revenue Growth September 6th 2024
紐交所:EVH收益和營業收入增長 2024年9月6日

Evolent Health is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

Evolent Health在投資者中很有名,許多聰明的分析師試圖預測未來的利潤水平。因此,我們建議查看這份免費報告,顯示共識預測。

A Different Perspective

不同的觀點

Evolent Health shareholders are up 19% for the year. But that return falls short of the market. If we look back over five years, the returns are even better, coming in at 33% per year for five years. Maybe the share price is just taking a breather while the business executes on its growth strategy. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Evolent Health , and understanding them should be part of your investment process.

Evolent Health的股東今年已經增加了19%。 但是這一回報略低於市場水平。如果我們回顧過去五年,回報甚至更好,達到每年33%的水平。也許股價只是在業務執行其增長策略時稍作休息。我發現從長期來看股價作爲業務表現的一種代理非常有趣。但要真正獲得洞察力,我們還需要考慮其他信息。例如,投資風險隨時存在。我們已經發現了2個警示信號,與Evolent Health有關,了解它們應該成爲您的投資過程的一部分。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論